Immunovia invitation to a teleconference on 24 August 2016
Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day
Immunovia invites you to a teleconference in connection with the publishing of the first half-year’s results for 2016. The conference call, which is expected to last for a maximum one hour, will be held in Swedish. After a presentation of the company by CEO Mats Grahn, you will have the opportunity to ask questions. Please dial in a few minutes before the conference call begins.
Date: August 24, 2016
Time: 10:00 (CET)
Phone numbers:
SE: +46 8 566 426 62
CH: +41 225 675 548
DE: +49 692 222 290 46
UK: +44 203 008 98 04
On Immunovias website under Investors / Financial Reports (http://immunovia.com/investors/financial-reports/) there will be an MP3 file for anyone who wants to listen to the conference afterwards. The file will be available within 2 hours after the conference has ended.
Half-year results are expected to be published at 08.30 a.m. (CET) on 24 August.
For questions and interview appointments:
ir@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
###
Tags: